Clinical Impact of Albumin-Bilirubin (ALBI) Score in Patients With Recurrent Esophageal Cancer After Curative Treatment
In Vivo · 2026
DOI: 10.21873/invivo.14454 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2026. Verfasst von Taiichi Kawabe und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Bilirubin, Neoplasm Recurrence, Local, Serum Albumin. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: The albumin-bilirubin (ALBI) score, which evaluates pretreatment liver function, has been reported as a prognostic factor in several malignancies. We conducted a retrospective study to clarify the prognostic impact of the ALBI score in patients with recurrent esophageal cancer. PATIENTS AND METHODS: We retrospectively reviewed the medical records and data of consecutive patients with recurrent esophageal cancer who received treatment, including best supportive care, at Yokohama City University from 2005 to 2022. The primary endpoint of the present study was overall survival (OS) after recurrence. The secondary endpoint was the association between the ALBI score and the treatment course after recurrence. RESULTS: Ninety patients were eligible for the present study. The median overall survival was 10.4 months (95% confidence interval=4.9-15.8 months). Based on previous studies and exploratory analyses of 1- and 3-year OS, the ALBI score cut-off was set at -2.80. The 90 patients were divided into the ALBI-low (ALBI score
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
- Department of Surgery, Yokohama City University, Yokohama, Japan.
- Department of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan; aoyamat@yokohama-cu.ac.jp.
- Department of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan; hashimoto.ita.ic@yokohama-cu.ac.jp.
Zitieren
APA
Kawabe, T., Aoyama, T., Hashimoto, I., Maezawa, Y., Sato, S., Kosaka, T., Kayashima, M., Takagi, M., Sekiguchi, K., Shimada, K., Okuda, N., Fukuda, M., Takahashi, M., Ju, M., Kamiya, N., Atsumi, Y., Kazama, K., Sugano, N., Tamagawa, A., …, & Yukawa, N. (2026). Clinical Impact of Albumin-Bilirubin (ALBI) Score in Patients With Recurrent Esophageal Cancer After Curative Treatment. In Vivo. https://doi.org/10.21873/invivo.14454
Vancouver
Kawabe T, Aoyama T, Hashimoto I, Maezawa Y, Sato S, Kosaka T, et al. Clinical Impact of Albumin-Bilirubin (ALBI) Score in Patients With Recurrent Esophageal Cancer After Curative Treatment. In Vivo. 2026. doi:10.21873/invivo.14454
BibTeX
@article{Kawabe2026,
author = {Kawabe, Taiichi and Aoyama, Toru and Hashimoto, Itaru and Maezawa, Yukio and Sato, Sho and Kosaka, Takashi and Kayashima, Miki and Takagi, Maki and Sekiguchi, Kohei and Shimada, Kiyoko and Okuda, Naoko and Fukuda, Momoko and Takahashi, Masaki and Ju, Mihwa and Kamiya, Natsumi and Atsumi, Yosuke and Kazama, Keisuke and Sugano, Nobuhiro and Tamagawa, Ayako and Saito, Aya and Yoshikawa, Takaki and Yukawa, Norio},
title = {Clinical Impact of Albumin-Bilirubin (ALBI) Score in Patients With Recurrent Esophageal Cancer After Curative Treatment},
journal = {In Vivo},
year = {2026},
doi = {10.21873/invivo.14454}
}
EUVIMED